Vanessa C. Williams

1.9k citations

33 papers · 1.4k indexed · h-index 18

Virology top 2%
- HIV Research and Treatment 10
Emergency Medicine top 1%
- HIV-related health complications and treatments 6
Infectious Diseases top 5%
- HIV/AIDS drug development and treatment 10
- HIV/AIDS Research and Interventions 4
Immunology and Allergy top 5%
Physiology top 5%
- Asthma and respiratory diseases 6
Pathology and Forensic Medicine
- Lymphoma Diagnosis and Treatment 6
Genetics
- Chronic Lymphocytic Leukemia Research 5
Psychiatry and Mental health
- Migraine and Headache Studies 2

Co-authors: Dorothy J. Margolskee Jules I. Schwartz Patrick Manning Richard M. Watson Paul M. O’Byrne Jaime E. Hernández Robin L. Fisher J Tyler Lonergan
Cited by: Virology Emergency Medicine Infectious Diseases
Partner nations: United States Netherlands United Kingdom

In The Last Decade

Vanessa C. Williams

32 papers receiving 1.4k citations

Peers

Countries citing papers authored by Vanessa C. Williams

Since Specialization

Citations

This map shows the geographic impact of Vanessa C. Williams's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vanessa C. Williams with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vanessa C. Williams more than expected).

Fields of papers citing papers by Vanessa C. Williams

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vanessa C. Williams. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vanessa C. Williams. The network helps show where Vanessa C. Williams may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Vanessa C. Williams, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Vanessa C. Williams Line = papers co-authored together Vanessa C. Williams links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL‐102): A phase 1 study Mehdi Hamadani,Morton Coleman,Ralph V. Boccia,Juraj Ďuraš,Martin Hutchings,Pier Luigi Zinzani,Raúl Córdoba,Mariana Bastos‐Oreiro,Vanessa C. Williams,Huiqing Liu,Michael Stouffs,Peter Langmuir,Juan‐Manuel Sancho	2023	1
2	CHOP Chemotherapy Followed by Tositumomab and Iodine-131 Tositumomab for Previously Untreated Diffuse Large B-cell Lymphoma John P. Leonard,Stephanie A. Gregory,Hedy Smith,Thierry Horner,Vanessa C. Williams,Patricia Giampietro,Thomas S. Lin	2016	2
3	Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study Marinus H. J. van Oers,Kazimierz Kuliczkowski,Lukáš Smolej,Mario Petrini,Fritz Offner,Sebastian Grosicki,Mark-David Levin,Ira Gupta,Jennifer L. Phillips,Vanessa C. Williams,Stephanie Manson,Steen Lisby,Christian H. Geisler	2015	84
4	Short‐term Safety and Tolerability of a Once‐Daily Fixed‐Dose Abacavir‐Lamivudine Combination versus Twice‐Daily Dosing of Abacavir and Lamivudine as Separate Components: Findings from the ALOHA Study Calvin Cohen,Marshall K. Kubota,Philip S. Brachman,William B. Harley,Stefan Schneider,Vanessa C. Williams,Denise Sutherland‐Phillips,Michael L. Lim,Rukmini Balu,Mark S. Shaefer	2008	10
5	Establishing a prognosis for functional outcome during coma recovery Theresa Pape,Sandra Lundgren,Allen W. Heinemann,Ann Guernon,Anita Giobbie‐Hurder,Wang Jia,Heidi Roth,Melanie Blahnik,Vanessa C. Williams	2006	14
6	A prospective, 96‐week study of the impact of Trizivir^®, Combivir^®/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral‐naive patients: effect of sex and ethnicity Princy Kumar,A Rodriguez‐French,Melanie Thompson,Karen T. Tashima,Dawn Averitt,Paul Wannamaker,Vanessa C. Williams,Mark S. Shaefer,Gary E. Pakes,Keith A. Pappa,Ess Study Team	2006	60
7	A Direct Comparison of Drug Susceptibility to HIV Type 1 from Antiretroviral Experienced Subjects as Assessed by the Antivirogram and PhenoSense Assays and by Seven Resistance Algorithms Lisa Ross,Ronan Boulmé,Robin Fisher,Jaime E. Hernández,Allison Florance,Jean-Claude Schmit,Vanessa C. Williams	2005	16
8	Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment Philip Keiser,Michael Sension,Edwin DeJesus,Allan Rodríguez,Jeffrey F Olliffe,Vanessa C. Williams,John H. Wakeford,Jerry Snidow,Anne Shachoy‐Clark,Julie W Fleming,Gary E. Pakes,Jaime E. Hernández,(unknown)	2005	31
9	Lack of Recurrence of Hyperlactatemia in HIV-Infected Patients Switched From Stavudine to Abacavir or Zidovudine J Tyler Lonergan,Grace A. McComsey,Robin L. Fisher,Peter Shalit,Thomas M. File,Douglas Ward,Vanessa C. Williams,Siegrid M. Hessenthaler,Laura E. Lindsey,Jaime E. Hernández	2004	15
10	Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine Grace A. McComsey,D. Paulsen,J Tyler Lonergan,Siegrid M. Hessenthaler,Charles L. Hoppel,Vanessa C. Williams,Robin L. Fisher,Catherine L. Cherry,Cathy White-Owen,Katherine A. Thompson,Steve T Ross,Jaime E. Hernández,Lisa Ross	2004	136
11	Improvement in Lipoatrophy Associated with Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus–Infected Patients Switched from Stavudine to Abacavir or Zidovudine: The Results of the TARHEEL Study Grace A. McComsey,Douglas Ward,Siegrid M. Hessenthaler,Michael Sension,Peter Shalit,J Tyler Lonergan,Robin L. Fisher,Vanessa C. Williams,Jaime E. Hernández,(unknown)	2004	148
12	Twice‐Daily Trizivir versus Combivir‐Abacavir in Antiretroviral‐Experienced Adults with Human Immunodeficiency Virus‐1 Infection: A Formulation‐Switch Trial (unknown),Margaret A. Fischl,Alfred F. Burnside,Charles Farthing,Melanie Thompson,Nicholaos Bellos,Vanessa C. Williams,Teresa L. Kauf,Paul Wannamaker,Mark S. Shaefer	2003	1
13	Pregnancy and perinatal outcomes in migraineurs using sumatriptan: a prospective study Stephen O’Quinn,Sara A. Ephross,Vanessa C. Williams,R. L. Davis,Donna Gutterman,Anthony W. Fox	1999	45
14	Oral pharmacokinetics and food interaction of the leukotriene D₄ receptor antagonist verlukast Jules I. Schwartz,Dorothy J. Margolskee,Thorir D. Bjornsson,Vanessa C. Williams,John Y.‐K. Hsieh,Charles C. Lin,John Rogers	1993	2
15	Bronchodilation with a Potent and Selective Leukotriene D ₄ (LTD ₄ ) Receptor Antagonist (MK-571) in Patients with Asthma Joseph N. Gaddy,Dorothy J. Margolskee,Robert K. Bush,Vanessa C. Williams,William W. Busse	1992	110
16	Leukotriene (LT) D₄ Is Involved in Antigen‐Induced Asthma: a Study with the LTD₄ Receptor Antagonist, MK‐571 J. B. Rasmussen,Dorothy J. Margolskee,L.‐O. Eriksson,Vanessa C. Williams,K Andersson	1991	20
17	Inhibition of Exercise-Induced Bronchoconstriction by MK-571, a Potent Leukotriene D₄–Receptor Antagonist Patrick Manning,Richard M. Watson,Dorothy J. Margolskee,Vanessa C. Williams,Jules I. Schwartz,Paul M. O’Byrne	1990	306
18	Regulation of Pancreatic Endocrine Function by Cholecystokinin: Studies with MK-329, a Nonpeptide Cholecystokinin Receptor Antagonist* Rodger A. Liddle,Barry J. Gertz,Shuji Kanayama,L Beccaria,Thomas W. Gettys,Ian L. Taylor,Robert J Rushakoff,Vanessa C. Williams,LISA D. COKER	1990	34
19	Assessment of MK-912, an α2-adrenoceptor antagonist, with use of intravenous clonidine J. B. Warren,C. T. Dollery,Richard W. Fuller,Vanessa C. Williams,Barry J. Gertz	1989	14
20	Clinical evaluation of a benzofuroquinolizine α2-adrenoceptor antagonist Barry J. Gertz,Peter H. Vlasses,Mario L. Rocci,LISA D. COKER,Vanessa C. Williams,Thorir D. Bjornsson,Keith Jones	1989	4

About Vanessa C. Williams

Vanessa C. Williams is a scholar working on Virology, Emergency Medicine and Infectious Diseases, having authored 33 papers that have together received 1.4k indexed citations. Recurring topics across this work include HIV Research and Treatment (10 papers), HIV/AIDS drug development and treatment (10 papers), Asthma and respiratory diseases (6 papers), HIV-related health complications and treatments (6 papers), Lymphoma Diagnosis and Treatment (6 papers), Chronic Lymphocytic Leukemia Research (5 papers), HIV/AIDS Research and Interventions (4 papers) and Migraine and Headache Studies (2 papers). The work is most often cited by research in Virology (336 citations), Emergency Medicine (415 citations) and Infectious Diseases (458 citations). Vanessa C. Williams has collaborated with scholars based in United States, Netherlands and United Kingdom. Frequent co-authors include Dorothy J. Margolskee, Jules I. Schwartz, Patrick Manning, Richard M. Watson, Paul M. O’Byrne, Jaime E. Hernández, Robin L. Fisher, J Tyler Lonergan, Grace A. McComsey and William W. Busse.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact